Rebecca Araujo

DocwireNews

Real-world data from a single institution showed concerningly low levels of long-term adherence to lenalidomide therapy for multiple myeloma (MM).For this <a href="https://journals.sagepub.com/doi/10.1177/1078155220980807">study</a>, researchers sought to evaluate lenalidomide adherence one year from treatment initiation. The study enrolled all 81 patients who began lenalidomide therapy at the Pescara Hospital in Pescara, Italy, between January 2012 and June 2016. The main outcomes were treatment adherence and efficacy. Adherence was calculated using a ratio between the received and prescribed daily dose. Efficacy was measured via progression-free survival (PFS) and <a href="https://www.docwirenews.com/docwire-pick/insurance-status-linked-to-survival-for-patients-with-multiple-myeloma/">overall survival</a> (OS) at one year follow-up.The average adherence to treatment after one year was 73%, with a variation of &plusmn;15%. Only 32% of patients achieved an adherence that was equal to or greater than 80%. Of those who achieved less than 80%, 4 adhered less than half the time, 11 between 51%-60% of the time, 22 between 61%-70%, and 18 between 71% and 80%. Five patients were &ldquo;completely adherent&rdquo; to the treatment, taking 100% of doses.Rates were similar across patient subgroups, which suggests that variables related to patient characteristics are not driving treatment adherence, according to the researchers.&ldquo;It is necessary to investigate and further delve into the causes of lack of adherence, conceivably to be related more to tolerability than dosage,&rdquo; they wrote.The study cohort achieved an average one-year PFS of 53.75% and OS of 88%. Lenalidomide adherence was found to be significantly associated with OS but not PFS (P=0.041).In conclusion, the authors wrote, &ldquo;The analysis of adherence in [patients with] multiple myeloma treated with lenalidomide one year from the beginning of therapy reveal a concerning lack of adherence. Moreover, the lack of correlation of the levels of adherence with patient-related variables shows that, in the case of multiple myeloma, adherence is not related to personal, social and environmental characteristics that may determine each patient&rsquo;s correct treatment implementation but is directly influenced by disease evolution.&rdquo;This <a href="https://journals.sagepub.com/doi/10.1177/1078155220980807">study</a> was published in the Journal of Oncology Pharmacy Practice.

Connie Rhee, MD

Joel M. Topf, MD, FACP

CKD Management and Cognition

NKF Spring Clinical Meetings 2025

Bradley Marder, MD

Gout Studies: Transplant Waitlisting and Bone Erosion

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Latest News

Low One-Year Adherence to Lenalidomide in Multiple Myeloma

Oncology

Real-world data from a single institution showed concerningly low levels of long-term adherence to lenalidomide therapy for multiple myeloma (MM). ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe